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developed in NSCLC, has been established here in SCLC. Patients on amrubicin
experienced less symptom deterioration during treatment.
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OBJECTIVES: Gain insights into Health Technology Assessment (HTA) agencies
expectations regarding Health-Related Quality of Life (HRQoL) for cost-effective-
ness evaluations of new medications for treating Castration-Resistant Prostate
Cancer (CRPC). METHODS: In January 2012, 61 HTA agencies websites were
scanned to identify HTAs of newmedications for the treatment of CRPC published
from 2005 to present. Only those evaluating the cost-effectiveness of new technol-
ogies were retained and analyzed for a better understanding of HTA agencies’
expectations regarding HRQoL in CRPC. RESULTS: 39 HTAs were identified, 12 of
which are currently in progress. The 27 published reports comprised 12 technology
appraisals, 9 horizon scanning reports and 6 literature reviews. Only 9 of the 12
technology appraisals evaluated cost-effectiveness, these included seven apprais-
als on three drugs: IQWiG (Germany) assessed abiraterone; NICE (England &Wales)
accepted docetaxel and rejected cabazitaxel; SMC (Scotland) rejected docetaxel
and cabazitaxel; CVZ (Netherlands) accepted cabazitaxel; PBAC (Australia) ac-
cepted docetaxel after two rejections and rejected cabazitaxel. Uncertainty regard-
ing HRQoL measures was the most often cited negative comment. For both do-
cetaxel and cabazitaxel, the absence of quality of life measures from the main
phase III trials and uncertainty around utility values were cited as reasons for
rejection by NICE, SMC and PBAC. The CVZ accepted cabazitaxel for temporary
reimbursement on the understanding that further subpopulation analysis and
more data on utilities will be needed. The IQWiG assessment of abiraterone com-
mented on uncertainties regarding the validity of the QoL questionnaire and re-
strictions in subgroup analyses. CONCLUSIONS: Our review indicates the need to
include comprehensive quality of life measures in phase III trials for new drugs to
treat CRPC, ensure these can be mapped into robust utility values and conduct
meaningful CRPC subpopulation analyses. Further insights will be gained in the
near future with the publication of CRPC HTAs currently in progress.
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OBJECTIVES:Data collected using patient reported outcomes (PRO) tools in clinical
trials provide unique information about patients’ experience with their treatment.
One of the major challenges with conducting clinical trials in linguistically diverse
countries such as India, however, is identifying and using PRO scales that are
linguistically validated in most of the representative regional languages. Lack of
availability of linguistically validated scales can limit the participation of a relevant
population from clinical trials. Therefore, the objective of this study was to deter-
mine if the PRO instruments used in clinical trials are linguistically validated in
local languages across the various regions in India. For this study we limited our
therapeutic area focus to clinical trials conducted in oncology. METHODS: A de-
tailed review of the registered trials in clinicaltrials.gov was conducted using qual-
ity of life (QoL) and oncology as keywords. Identified articles (n103)were screened
to exclude trials where QoL was not measured and studies with n 	 30. ProQoLID
and official websites of questionnaires were used to determine the availability of
translations and linguistic validity of the questionnaires included in clinical trials.
RESULTS: EQ-5D is the most commonly used generic instrument in oncology trials
and is validated in most 11 Indian languages. EORTC-QLQC30, EORTC-QLQH&N35,
EORTC-QLQBR23 and EORTC-QLQLC13 are the most commonly used cancer spe-
cific instruments and are validated in approximately 10 Indian languages. None of
the generic or disease specific cancer instruments have been translated or linguis-
tically validated for the Eastern & North-Eastern regions in India in languages such
as Oriya, Santhali, Assamese, and Manipuri thereby limiting the participation of
patients from these regions in clinical trials. CONCLUSIONS: The results of our
analysis indicate that future efforts need to focus on translating and validating PRO
instruments in 14 different Indian languages that should include the North Eastern
regions of India.
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OBJECTIVES: Antidepressants (ADs) are primarily used to treat depression and anxi-
ety among individuals with cancer and depression; however ADs are also being used
for symptomatic relief from hot-flashes, neuropathic-pain, and fatigue in this popu-
lation. Although there is a lack of robust evidence on the effectiveness of ADs in this
population, and conflicting reports of a possible association between AD use and risk
of recurrenceof certaincancersexists;ADsarestill beingprescribed in thispopulation.
Thus, the objective of this studywas to systematically review the extent of anyADuse
among individuals with cancer. METHODS: A systemic literature search was con-
ducted using 4 electronic databases (PubMed, CINHAL, PsychINFO, and Web-of-Sci-
ence), and cross-referencing. Studies starting from1975 to 2011, and fromall countries
were assessed. Eligibility criteria used for the extraction of studies included: 1)full
articles published in peer-reviewed journals in English-language only; 2)observational
studieswithdata onanyuse or prescription ofADs; and 3)adults and children aged1
year diagnosed with cancer (all types and stages of cancer were included). Studies on
the use of psychotropic agents other thanADs or psychotherapywere excluded. After
data extraction, number and percentages of individuals with cancer using ADs were
calculated.RESULTS:The search yielded 1880 studies, 14 ofwhichmet thepredefined
inclusion criteria. Overall, the rates of AD use ranged from 1%-26% in varying sub-
groupsof cancerpatients;with lower rates inpediatric cancerpatients (7%-12.3%), and
in those with advanced-stage cancers (7.4%-16%). Rates also varied according to the
type of cancers: breast (11.5%-34%), prostate (7%-18.8%), colon (7.5%-17.3%) and lung
(7.2%-13.7%). The rates were higher among individuals with cancer and clinically di-
agnosed depression (12%-66.6%). CONCLUSIONS: Our descriptive results suggest
that ADusemay be associatedwith cancer site and stage, and presence of clinically
diagnosed depression; and is lower in pediatric and advanced-stage cancer pa-
tients.
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OBJECTIVES: Hypomethylating agents (HMAs), decitabine and azacitidine, are in-
dicated for use in treatment of myelodysplastic syndromes (MDS), however only a
minority of patients receive HMAs. Our objective was to examine patterns of treat-
ment associated with FDA-approved 5-day decitabine (DEC-5) and 7-day azaciti-
dine (AZA-7) and off-label 5-day azacitidine (AZA-5) in MDS patients. METHODS:
We identified MDS patients with an initial HMA treatment between July 1, 2005 to
June 30, 2009 in 2 large insurance claims databases. Index date was the date of
initial HMA treatment. Patients were stratified into: DEC-5, AZA-7, or AZA-5, based
on their first cycle of treatment and were followed for 6 months. We described the
number of unique cycles of index treatment and treatment gaps (days of missed
treatment) in these groups. RESULTS:We identified 18,706 patients with MDS; 546
were treated with HMAs and were included in the study (156 received DEC-5, 176
received AZA-5 and 214 received AZA-7). Mean age was similar across groups:
68.8-71.2 years. Neutropenia was more common before treatment initiation in the
DEC-5 (34.6%) group than in AZA-5 (22.7%) and AZA-7 (26.6%; p.05) groups. There
were 1,701 treatment cycles: 431 DEC-5 (per patient mean:2.8; median:2), 586 for
AZA-5 (mean:3.3; median:3), and 684 for AZA-7 (mean:3.2; median:3) (p0.05 for
means). DEC-5 cycles had the fewest gaps: 94.9% had no treatment gaps, compared
to 89.1% for AZA-5 and 23.4% for AZA-7. Among DEC-5 cycles, 3.2% had a 2 day gap,
compared to 7.2% for AZA-5 and 66.5% for AZA-7 (p0.001). CONCLUSIONS: In this
retrospective claims analysis, few MDS patients were treated with HMAs. Among
those who received HMAs, decitabine patients were more likely to have prior neu-
tropenia. Between the 2 FDA-approved regimens, DEC-5 and AZA-7, there were
significantly fewer gaps with decitabine treatment. More treatment gaps were ob-
served with use of longer AZA regimen.
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OBJECTIVES: Comprised of carcinoid and pancreatic neuroendocrine tumors
(NETs), gastrointestinal NETs give rise to diverse clinical syndromes. Current treat-
ment guidelines lack some specificity. We summarize an expert panel consensus
on medical treatment of well-differentiated (grade 1-2) unresectable midgut NETs.
METHODS:ThemodifiedRAND/UCLADelphi processwas used to collectNET treat-
ment appropriateness ratings. The process involved recruitment of physician ex-
perts (e.g., by specialty, geography, practice), literature review, and collection of
ratings before and after a face-to-face discussion. Experts and moderator were
blinded to funding source. Patient scenarios were rated on a 1-9 scale on appropri-
ateness of various therapies and were labeled as appropriate, inappropriate, or
uncertain. Scenarios with2 ratings in 1-3 and2 in 7-9 range were considered to
have disagreement. RESULTS: Panelists (age: 38-63 years) were from northeast,
midwest, south, and west regions. Panelists had practiced for a mean 15.5 years
and reported seeing 25 to 800NETpatients per year. Panelists rated 202 scenarios in
midgut NETs. The proportion on which there was disagreement decreased from
11.7% (23 scenarios) before the meeting to 4.5% (9) after. After the meeting, 49% (99
scenarios) were rated inappropriate, 29.7% (60) were uncertain, and 16.8% (34) were
appropriate. Resulting consensus statements include: 1) it is appropriate to use
somatostatin analogs as 1st-line therapy in all patients; 2) it is appropriate to in-
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